Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy

Free Radical Biology and Medicine

Volumn 48, Issue 3, 2010, Pages 457-467

  Mukhopadhyay, Partha ^a   Rajesh, Mohanraj ^a   Pan, Hao ^a,b   Patel, Vivek ^a   Mukhopadhyay, Bani ^a   Bátkai, Sándor ^a   Gao, Bin ^a   Haskó, György ^c   Pacher, Pál ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Cannabinoid receptors; Free radicals; Inflammation; Nephropathy; Nitrosative stress; Oxidative stress

Indexed keywords

3 NITROTYROSINE; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; CANNABINOID 2 RECEPTOR; CISPLATIN; CREATININE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; ENDOCANNABINOID; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NITROGEN; POLY(ADENOSINE DIPHOSPHATE RIBOSE); REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; HISTOPATHOLOGY; INFLAMMATION; KIDNEY DISEASE; KIDNEY FUNCTION; KNOCKOUT MOUSE; MALE; MOUSE; NEPHROTOXICITY; NEUTROPHIL CHEMOTAXIS; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CANNABINOIDS; CASPASES; CISPLATIN; IN SITU NICK-END LABELING; INFLAMMATION; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LIPID PEROXIDATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEROXIDASE; POLY(ADP-RIBOSE) POLYMERASES; REACTIVE OXYGEN SPECIES; RECEPTOR, CANNABINOID, CB2; TYROSINE;

MUS;

EID: 73449112234     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.11.022     Document Type: Article

References (51)

1. Ries F., and Klastersky J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am. J. Kidney Dis. 8 (1986) 368-379
2. Schrier R.W. Cancer therapy and renal injury. J. Clin. Invest. 110 (2002) 743-745
3. Yamate J., Sato K., Ide M., Nakanishi M., Kuwamura M., Sakuma S., and Nakatsuji S. Participation of different macrophage populations and myofibroblastic cells in chronically developed renal interstitial fibrosis after cisplatin-induced renal injury in rats. Vet. Pathol. 39 (2002) 322-333
4. Faubel S., Lewis E.C., Reznikov L., Ljubanovic D., Hoke T.S., Somerset H., Oh D.J., Lu L., Klein C.L., Dinarello C.A., and Edelstein C.L. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J. Pharmacol. Exp. Ther. 322 (2007) 8-15
5. Matsushima H., Yonemura K., Ohishi K., and Hishida A. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J. Lab. Clin. Med. 131 (1998) 518-526
6. Davis C.A., Nick H.S., and Agarwal A. Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J. Am. Soc. Nephrol. 12 (2001) 2683-2690
7. Chirino Y.I., Hernandez-Pando R., and Pedraza-Chaverri J. Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacol. 4 (2004) 20
8. Chirino Y.I., Trujillo J., Sanchez-Gonzalez D.J., Martinez-Martinez C.M., Cruz C., Bobadilla N.A., and Pedraza-Chaverri J. Selective iNOS inhibition reduces renal damage induced by cisplatin. Toxicol. Lett. 176 (2008) 48-57
9. Racz I., Tory K., Gallyas Jr. F., Berente Z., Osz E., Jaszlits L., Bernath S., Sumegi B., Rabloczky G., and Literati-Nagy P. BGP-15-a novel poly(ADP-ribose) polymerase inhibitor-protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem. Pharmacol. 63 (2002) 1099-1111
10. Ramesh G., and Reeves W.B. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 110 (2002) 835-842
11. Zhang B., Ramesh G., Norbury C.C., and Reeves W.B. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int. 72 (2007) 37-44
12. Mechoulam R., Fride E., and Di Marzo V. Endocannabinoids. Eur. J. Pharmacol. 359 (1998) 1-18
13. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
14. Pacher P., Batkai S., and Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58 (2006) 389-462
15. Batkai S., Osei-Hyiaman D., Pan H., El-Assal O., Rajesh M., Mukhopadhyay P., Hong F., Harvey-White J., Jafri A., Hasko G., Huffman J.W., Gao B., Kunos G., and Pacher P. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J. 21 (2007) 1788-1800
16. Rajesh M., Pan H., Mukhopadhyay P., Batkai S., Osei-Hyiaman D., Hasko G., Liaudet L., Gao B., and Pacher P. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J. Leukocyte Biol. 82 (2007) 1382-1389
17. Montecucco F., Lenglet S., Braunersreuther V., Burger F., Pelli G., Bertolotto M., Mach F., and Steffens S. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J. Mol. Cell. Cardiol. 46 (2009) 612-620
18. Zhang M., Adler M.W., Abood M.E., Ganea D., Jallo J., and Tuma R.F. CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvasc. Res. 78 (2009) 86-94
19. Steffens S., Veillard N.R., Arnaud C., Pelli G., Burger F., Staub C., Karsak M., Zimmer A., Frossard J.L., and Mach F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434 (2005) 782-786
20. Rajesh M., Mukhopadhyay P., Batkai S., Hasko G., Liaudet L., Huffman J.W., Csiszar A., Ungvari Z., Mackie K., Chatterjee S., and Pacher P. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am. J. Physiol.,Heart Circ. Physiol. 293 (2007) H2210-2218
21. Batkai S., Rajesh M., Mukhopadhyay P., Hasko G., Liaudet L., Cravatt B.F., Csiszar A., Ungvari Z., and Pacher P. Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am. J. Physiol., Heart Circ. Physiol. 293 (2007) H909-H918
22. Maresz K., Pryce G., Ponomarev E.D., Marsicano G., Croxford J.L., Shriver L.P., Ledent C., Cheng X., Carrier E.J., Mann M.K., Giovannoni G., Pertwee R.G., Yamamura T., Buckley N.E., Hillard C.J., Lutz B., Baker D., and Dittel B.N. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. 13 (2007) 492-497
23. Sagredo O., Gonzalez S., Aroyo I., Pazos M.R., Benito C., Lastres-Becker I., Romero J.P., Tolon R.M., Mechoulam R., Brouillet E., Romero J., and Fernandez-Ruiz J. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 57 (2009) 1154-1167
24. Storr M.A., Keenan C.M., Zhang H., Patel K.D., Makriyannis A., and Sharkey K.A. Activation of the cannabinoid 2 receptor (CB(2)) protects against experimental colitis. Inflamm. Bowel Dis. 15 (2009) 1678-1685
25. Pacher P., and Gao B. Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. Am. J. Physiol., Gastrointest. Liver Physiol. 294 (2008) G850-854
26. Michalski C.W., Laukert T., Sauliunaite D., Pacher P., Bergmann F., Agarwal N., Su Y., Giese T., Giese N.A., Batkai S., Friess H., and Kuner R. Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology 132 (2007) 1968-1978
27. Pacher P., and Hasko G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br. J. Pharmacol. 153 (2008) 252-262
28. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce?. Nat. Rev., Drug Discovery 7 (2008) 438-455
29. Pertwee R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 156 (2009) 397-411
30. Pisanti S., and Bifulco M. Endocannabinoid system modulation in cancer biology and therapy. Pharmacol. Res. 60 (2009) 107-116
31. Hanus L., Breuer A., Tchilibon S., Shiloah S., Goldenberg D., Horowitz M., Pertwee R.G., Ross R.A., Mechoulam R., and Fride E. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. USA 96 (1999) 14228-14233
32. Pan H., Mukhopadhyay P., Rajesh M., Patel V., Mukhopadhyay B., Gao B., Hasko G., and Pacher P. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J. Pharmacol. Exp. Ther. 328 (2009) 708-714
33. Pan H., Shen Z., Mukhopadhyay P., Wang H., Pacher P., Qin X., and Gao B. Anaphylatoxin C5a contributes to the pathogenesis of cisplatin-induced nephrotoxicity. Am. J. Physiol., Renal Physiol. 296 (2009) F496-504
34. Moon K.H., Hood B.L., Mukhopadhyay P., Rajesh M., Abdelmegeed M.A., Kwon Y.I., Conrads T.P., Veenstra T.D., Song B.J., and Pacher P. Oxidative inactivation of key mitochondrial proteins leads to dysfunction and injury in hepatic ischemia reperfusion. Gastroenterology 135 (2008) 1344-1357
35. Mukhopadhyay P., Rajesh M., Batkai S., Kashiwaya Y., Hasko G., Liaudet L., Szabo C., and Pacher P. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am. J. Physiol., Heart Circ. Physiol. 296 (2009) H1466-H1483
36. Pacher P., Liaudet L., Bai P., Mabley J.G., Kaminski P.M., Virag L., Deb A., Szabo E., Ungvari Z., Wolin M.S., Groves J.T., and Szabo C. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107 (2003) 896-904
37. Mukhopadhyay P., Batkai S., Rajesh M., Czifra N., Harvey-White J., Hasko G., Zsengeller Z., Gerard N.P., Liaudet L., Kunos G., and Pacher P. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J. Am. Coll. Cardiol. 50 (2007) 528-536
38. Murikinati, S.; Juttler, E.; Keinert, T.; Ridder, D. A.; Muhammad, S.; Waibler, Z.; Ledent, C.; Zimmer, A.; Kalinke, U.; Schwaninger, M. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J. 2009. doi:10.1096/fj.09-141275.
39. Benito C., Tolon R.M., Pazos M.R., Nunez E., Castillo A.I., and Romero J. Cannabinoid CB2 receptors in human brain inflammation. Br. J. Pharmacol. 153 (2008) 277-285
40. Izzo A.A., and Camilleri M. Cannabinoids in intestinal inflammation and cancer. Pharmacol. Res. 60 (2009) 117-125
41. Ischiropoulos H., Zhu L., and Beckman J.S. Peroxynitrite formation from macrophage-derived nitric oxide. Arch. Biochem. Biophys. 298 (1992) 446-451
42. McCord J.M., and Fridovich I. The biology and pathology of oxygen radicals. Ann. Intern. Med 89 (1978) 122-127
43. Radi R., Beckman J.S., Bush K.M., and Freeman B.A. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch. Biochem. Biophys. 288 (1991) 481-487
44. Szabo C., Ischiropoulos H., and Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat. Rev., Drug Discovery 6 (2007) 662-680
45. Pacher P., Beckman J.S., and Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87 (2007) 315-424
46. Geiszt M., Kopp J.B., Varnai P., and Leto T.L. Identification of renox, an NAD(P)H oxidase in kidney. Proc. Natl. Acad. Sci. USA 97 (2000) 8010-8014
47. Levrand S., Vannay-Bouchiche C., Pesse B., Pacher P., Feihl F., Waeber B., and Liaudet L. Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo. Free Radic. Biol. Med. 41 (2006) 886-895
48. Beckman J.S. Understanding peroxynitrite biochemistry and its potential for treating human diseases. Arch. Biochem. Biophys. 484 (2009) 114-116
49. Liaudet L., Vassalli G., and Pacher P. Role of peroxynitrite in the redox regulation of cell signal transduction pathways. Front. Biosci. 14 (2009) 4809-4814
50. Han K.H., Lim S., Ryu J., Lee C.W., Kim Y., Kang J.H., Kang S.S., Ahn Y.K., Park C.S., and Kim J.J. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc. Res. 84 (2009) 378-386
51. Guzman M. Cannabinoids: potential anticancer agents. Nat. Rev., Cancer 3 (2003) 745-755